Stockscreener 앱 받기
5.74
3.42%
0.19
시간 외 거래:
5.74
전일 마감가:
$5.55
열려 있는:
$5.55
하루 거래량:
411.13K
Relative Volume:
2.13
시가총액:
$84.12M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.928
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
+3.05%
1개월 성능:
+4.36%
6개월 성능:
-73.15%
1년 성능:
-75.19%
1일 변동 폭
$5.4972
$6.10
1주일 범위
$5.12
$6.10
52주 변동 폭
$3.1301
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
5.74 | 84.12M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
When the Price of (JSPR) Talks, People Listen - news.stocktradersdaily.com
Draig Therapeutics launches with $140 million - The Pharma Letter
Solu Therapeutics appoints new COO - The Pharma Letter
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results - TipRanks
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU market drives stock outlook - Investing.com Nigeria
Jasper releases new data on briquilimab from SPOTLIGHT trial - The Pharma Letter
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | - GuruFocus
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | JSPR Stock News - GuruFocus
Jasper Therapeutics Reports Positive Data from 180mg Cohort - GlobeNewswire
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized - Investing.com Canada
Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
Wellington Management Group LLP Boosts Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Trend Tracker for (JSPR) - news.stocktradersdaily.com
Is Monster Beverage Stock Outperforming the S&P 500? - The Globe and Mail
Jane Street Group LLC Sells 2,502 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Warren Buffett Is Ready to Invest $100 Billion in a Stock That Meets These 3 Criteria - The Globe and Mail
Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025 - Nasdaq
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Breakthrough Clinical Data: Jasper's Briquilimab Shows Promise in Treating Resistant Urticaria Cases - Stock Titan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance
Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market - TipRanks
Bank of America Corp DE Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Market Analysis: May 26th, 2025 - The Globe and Mail
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment By Investing.com - Investing.com South Africa
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stake Lifted by Deutsche Bank AG - Defense World
Spotify Stock's Rally Still Has Legs To Run Higher - The Globe and Mail
Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World
Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus
(JSPR) Trading Report - news.stocktradersdaily.com
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World
Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Jasper Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus
Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus
UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jasper Therapeutics Inc 주식 (JSPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
0.27%
0.50%
자본화:
|
볼륨(24시간):